The v-myb oncogene and its cellular homolog c-myb encode sequence-specific DNA-binding proteins which 
tion, both v-Myb and c-Myb are capable of activating transcription from promoters containing Myb-binding sites in animal cells (31, 38, 51, 71) . A Myb-regulated gene, mim-1, has been identified by using a subtractive hybridization screening approach (50) . Three Myb-binding sites were found in the promoter region of the mim-1 gene.
The central portion of c-Myb contains a transcriptional activation domain identified by assaying various GAL4-Myb fusion proteins and by mutational analysis of v-Myb (40, 60, 71) . In addition, a negative regulatory domain has been revealed by deletions of the C-terminal sequences of c-Myb which increased its transactivation activity (14, 36, 60) . The N-terminal portion of c-Myb, which is missing in v-Myb, has also been implicated as a regulatory domain (12a, 43) .
The general transcriptional machinery and mechanism are well conserved during evolution (57) . For example, yeast and human TFIIDs can functionally substitute for each other (5, 6) . Various mammalian transcription factors, such as the glucocorticoid receptor, estrogen receptor, and thyroid hormone receptor, have been shown to activate transcription from promoters containing appropriate response elements in a hormone-dependent fashion in S. cerevisiae (46, 56, 62) . Therefore, it was of interest to examine Myb transactivation function in S. cerevisiae, a system that is relatively simple, easy to manipulate, and genetically well defined.
We report here the analysis of the transactivation abilities of v-Myb, c-Myb, and a series of mutants and VP16 fusion proteins in S. cerevisiae. Our data showed that the Myb transactivation domain previously defined by GAL4-Myb fusions was sufficient for transactivation by v-Myb in S. cerevisiae but not in animal cells. In addition, we found that c-Myb was a much stronger transactivator in S. cerevisiae than was a v-Myb-like truncation, whereas the converse results were obtained with animal cells.
MATERIALS AND METHODS
marker and the 2 ,um origin, was kindly provided by R.
Daniel Gietz (21) and was used to construct various Myb expression vectors. The advantage of using YEplac112 was that it is a relatively small plasmid lacking many restriction enzyme sites, so that myb and its mutants could be easily cloned into the expression vector.
The GALI, 10 promoter was obtained by cutting the plasmid pBM150 (35) with EcoRI and BamHI and was cloned into the multiple cloning sites of YEplac112 to generate the plasmid YEplacll2galP. The EcoRI site was then removed from YEplac112galP, and a ClaI linker was added to the end-filled HindIII site in the multiple cloning sites of the plasmid. The XbaI-ClaI v-myb-vpl6 fragment derived from A5-MybVP was cloned into the multiple cloning sites to generate the vector YGMV for the expression of v-Myb-VP16 fusion protein. A5-MybVP contains the entire v-mybvpl6 open reading frame (31) into which five A's were introduced at the translation initiation site by using the XbaI-SacI adaptor (underlined) as follows: Relevant restriction enzyme sites and the predicted amino acid sequence are also shown. The v-Myb specific residues start at NR. This alteration was designed to increase the translational efficiency in S. cerevisiae (13) . The SaiI-ClaI v-myb-derived fragment from MT7dGE (66) was used to replace the vpl6 portion of YGMV to give rise to YGdGE (Fig. 1A) , in which v-Myb expression was driven by the inducible GALl promoter. In order to construct an expression vector for the v-Myb protein under the control of the yeast constitutive ADHI promoter, YGdGE was cut with BamHI and Narl to delete the GAL1, 10 promoter, end filled, and ligated to recreate a unique BamHI site which was used later to insert the ADHI promoter. The SphI-HindIII fragment of the ADHI promoter, which has been shown to be functionally equivalent to the entire ADHI promoter, was obtained from the plasmid pMA424 (45) . A BamHI linker was added to both blunted ends of the SphI-HindIII fragment; addition was followed by BamHI digestion. The fragment was then gel purified and ligated to the unique BamHI site in the vector described above to generate YDdGE (Fig. 1B) . The constitutive expression vector for v-Myb-VP16 was constructed from YDdGE by replacing the v-myb sequence with the v-myb-vpl6 sequence. The v-Myb (v-MybdGE) protein used in this study lacks gag-and env-encoded sequences found in AMV v-Myb and has been previously shown to transactivate promoters containing Myb-binding sites and to transform chicken myeloid cells (25, 30) . All the v-Myb mutants were built in the YDdGE vector in order to compare them in the same context. The linker insertion mutants 281, 364, 752, and 859; the C-terminal deletion mutants LX1, LX2, and LX3; and the amino acid substitution mutant C65S were described previously (25, 30, 40) . The mutant 859 used in this study contained a two-codon deletion at the Bsu 361 site. Yeast expression vectors for these v-Myb mutants were constructed by substitution of the appropriate wild-type fragments of v-Myb in YDdGE with the corresponding mutant fragments from the mutant constructs. Yeast expression vectors for mutants 281, 364, and C65S in the context of v-Myb-VP16 were constructed in a similar way. The expression vector for v-MybdB was constructed from YDdGE by in-frame deletion of the EcoRI-EcoRI fragment comprising (34) . The XhoI-SaiI fragments of EW5(-)CAT and EM5(-)CAT were cloned into the XhoI site upstream of the CYCl TATA box of pSS, giving rise to yeast reporter plasmids SW5(+), SW5(-), SM5(+), and SM5(-) (Fig. 1C) . All the reporter gene constructs were confirmed by DNA sequencing.
Yeast growth and yeast reporter strains. The protocols for growth and maintenance of yeast strains were as described previously (27 yeast reporter strains were transformed with various activator plasmids and grown in selective media lacking tryptophan. A sterile filter paper (Whatman 1 or VWR grade 413) was placed onto the plate with transformants, lifted, and then immersed in liquid nitrogen for about 5 s to permeabilize the yeast cells and thawed at room temperature for about 2 min. The filter was then laid onto another filter paper presoaked with 0.3 mg of X-Gal per ml of substrate solution and incubated at 30°C. The blue color of positive colonies was detected between 1 and 24 h. The other assay was the quantitative liquid culture 13-Gal assay, in which cells were allowed to grow in appropriate selective media to an optical density at 600 nm (OD6.) of 0.5 to 1.0 and permeabilized with chloroform and sodium dodecyl sulfate (SDS). The ,B-Gal activity was assayed as described by Miller (47) (34) . Five tandem copies of the wild-type mim-L4, a strong Myb-binding site (50) , were inserted upstream of the minimal CYCI promoter in pSS in either orientation to give rise to the reporter plasmids SW5(+) and SW5(-) (Fig. 1) . A matched pair of plasmids, SM5(+) and SM5(-), which contained five tandem copies of a mutant v-Myb-VP16 was expressed. In the absence of galactose induction, no transactivation was observed. Only the reporter plasmids containing the wild-type Myb-binding sites could be transactivated, and similar results were obtained with both orientations of these sites. These results were consistent with a previous report that chicken c-Myb could transactivate transcription in S. cerevisiae (58) . We constructed similar activator plasmids with the constitutive ADHI promoter instead (Fig. 1) . However, when 13-Gal expression in individual colonies was measured by the filter X-Gal assay, transformants without Myb proteins or wild-type Myb-binding sites consisted of a mixture of blue and white colonies, including some blue colonies with white centers. Some blue colonies were observed in S. cerevisiae not expressing v-Myb or v-Myb-VP16 and in S. cerevisiae bearing the mutant reporter plasmid. These results suggested that although transactivation could be measured, there was significant variation in the basal transcription of both reporter genes in individual transformants.
Because promoter were transformed into these reporter strains. Liquid 1-Gal assays gave results at a lower level than but qualitatively similar to those obtained with the high-copynumber plasmid reporter strains described above. However, when the 3-Gal production in individual transformants was tested by the filter X-Gal assay, no background activity was detected in the absence of Myb proteins (Fig. 2) . In addition, the mutant reporter strain showed no 1-Gal activity regardless of the presence or absence of v-Myb or v-Myb-VP16. Therefore, in the integrated reporter strain transactivation appeared to be strictly dependent on both the presence of wild-type Myb-binding sites and Myb protein production.
Transactivation by a series of v-Myb and v-Myb-VP16 mutants in S. cerevisiae and animal cells. Because v-Myb and v-Myb-VP16 can transactivate in S. cerevisiae, we were interested in testing a number of v-Myb mutants in S. cerevisiae and comparing the results with those from animal cells. Therefore, a series of v-Myb and v-Myb-VP16 mutants were expressed in the yeast reporter strain YSW5(+) under the control of the ADHI promoter, and their transactivation activities were scored with both the filter X-Gal assay (data not shown) and the liquid 1-Gal assay (Fig. 3) . Parallel experiments were carried out in which proviral constructs encoding the same Myb mutants and the reporter plasmid EW5(+)CAT, possessing the same wild-type mim-M sites upstream of a simple E1B TATA box and a CAT reporter gene, were transiently cotransfected into QT6 cells, and CAT assays were performed (Fig. 3) sufficient for transactivation by v-Myb in S. cerevisiae but not in animal cells.
To determine whether the different activities of these mutants were due to their differential protein production, we measured their expression levels by immunoblotting. v-Myb, v-Myb-VP16, and their mutants were all expressed at approximately the same level in yeast cells (Fig. 4) . In each case, the uppermost immunoreactive band has a relative mobility consistent with that of the expected full-length protein product. All Myb proteins were also expressed at similar levels in transfected animal cells (data not shown).
Full-length c-Myb is more active than a v-Myb-like truncation in S. cerevisiae. Using the same approach, we also compared the transactivation activities of c-Myb (CCC) and N-terminally truncated (dCC), C-terminally truncated (CCd), and doubly truncated (dCd) c-Myb mutants in yeast and animal cells (Fig. 5) . The 8 and 12 to 19) or polyclonal anti-Myb-BP2 antibodies (lanes 9 to 11). The relative mobilities of molecular mass markers are indicated by short lines to the left of lane 12 (26, 36, 48, 58, 84, 116 , and 180 kDa, from bottom to top). The mobilities of the four smallest markers are indicated to the left of lane 1.
(dCd) was twofold more active than either full-length c-Myb or v-Myb in animal cells. Yeast cells expressing dCC or CCd exhibited about 50% of the 1-Gal activity compared with those expressing the full-length c-Myb, suggesting that both N and C termini are required for the full transactivation capacity of c-Myb in S. cerevisiae. Therefore, it was not surprising that dCd, the doubly truncated form of c-Myb, was less active than singly truncated c-Myb mutants CCd and dCC. In order to rule out the possibility that the differential protein expression levels caused differential activities for various mutants, we performed immunoblotting with extracts from strains transformed with the expression plasmids for c-Myb and its mutants. As illustrated in Fig. 4 , both singly truncated c-Myb mutants CCd and dCC were detected in amounts almost equal to that of full-length c-Myb and the doubly truncated mutant dCd was expressed at a higher level, possibly because of its smaller size.
These results from yeast cells were different from previous reports which demonstrated that in animal cells, truncation found that the N-terminally truncated or doubly truncated c-Myb mutants dCC and dCd were more active than c-Myb, whereas the C-terminally truncated CCd was not (Fig. 5) . DISCUSSION The nuclear oncoprotein v-Myb and its cellular counterpart, c-Myb, have been shown to be transcriptional activators in animal cells (31, 38, 50, 51, 71) . The DNA-binding domain and the transactivation domain have been assigned to the highly conserved N-terminal Myb repeats and the central acidic portion (residues 204 to 254 relative to v-Myb) of these proteins, respectively (19, 28, 39, 40, 71) . A negative regulatory domain has also been mapped within the C terminus of the c-Myb protein that has been deleted in v-Myb (14, 29, 36, 60 25 -fold in animal cells. Linker insertion 859 within the acidic region had 80% of wild-type activity in S. cerevisiae, but only 14% in animal cells. Furthermore, deletion of a region C terminal to the previously defined activation domain (LX3) which contains a heptad leucine repeat had 66% of wild-type activity in S. cerevisiae, but only 8% in animal cells. The C-terminal domain of v-Myb which is missing in LX3 is also required in animal cells for transactivation of the herpes simplex virus-thymidine kinase promoter which does not itself contain Myb-binding sites (3, 31) . These results imply that the minimal transcriptional activation domain as defined by GAL4-Myb fusion proteins (71) is sufficient for transcriptional activation in S. cerevisiae but not in animal cells in the context of native v-Myb. Interestingly, the domain of v-Myb which is deleted in LX3 is also required for full transforming activity in myeloid cells (30) . This region of Myb is absent in the Gag-Myb-Ets oncoprotein of the avian E26 leukemia virus (41, 53) , suggesting that Ets can functionally substitute for this essential domain of AMV v-Myb.
We have also compared transactivation by the nontransforming full-length c-Myb protein and various oncogenic truncations in yeast and animal cells. In S. cerevisiae, full-length c-Myb is 400% as active as a v-Myb-like double truncation, whereas in animal cells c-Myb is only 50% as active as the same truncation. This implies that the negative regulation of c-Myb by its own termini requires additional proteins or small molecules which are not present in S. cerevisiae. This is reminiscent of previous studies of v-erbA, which is a dominant repressor of transactivation in animal cells but which activates transcription in a hormone-regulated manner in S. cerevisiae (56) .
We also noted that C-terminal truncation of c-Myb did not result in a significant increase in transactivation of our test promoter activity in animal cells, in contrast to previous observations that the C-terminal portion of the protein acts as an inhibitory domain for c-Myb transactivation (14, 60) .
However, N-terminal truncation increased the transactivation of the same promoter twofold in animal cells. The difference may be due to the different promoters used in this and previous studies and emphasizes the need for obtaining additional bona fide target promoters which are directly regulated by the Myb proteins.
The yeast assay system we have established for v-Myb and c-Myb will enable us to further investigate the mechanism of v-Myb and c-Myb transactivation by using genetic screening protocols to assay random mutants of the Myb proteins. As mentioned above, the differential action of full-length and oncogenically truncated forms of c-Myb in yeast and animal cells might be due to factors differentially present in these cell backgrounds. The availability of the two-hybrid system to screen for protein-protein interactions (9, 16) should facilitate the detection and identification of a putative factor(s) interacting with v-Myb and c-Myb. The success of this approach has been shown by recent studies which have identified a mammalian SRF-associated protein by screening libraries in S. cerevisiae (12) .
